Rayonier Advanced Materials (RYAM) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
16 Jan, 2026Executive summary
Q3 2024 net sales reached $401 million, up 9% year-over-year, driven by High Purity Cellulose (HPC) price and volume gains, despite lower Paperboard prices and commodity volumes.
Adjusted EBITDA for Q3 2024 was $51 million, up 113% year-over-year, with margins nearly doubling to 12.7%.
Net loss from continuing operations was $33 million, including a $25 million non-cash impairment and $7 million in suspension charges related to Temiscaming.
Major events included a $700 million term loan refinancing, a fire at the Jesup plant with a $10 million EBITDA impact, and indefinite suspension of Temiscaming HPC operations.
Strategic initiatives improved liquidity, reduced debt, and reduced non-HPC commodity exposure to 4% of revenue.
Financial highlights
Adjusted free cash flow year-to-date was $99 million, up from $27 million in the prior year period.
Gross margin for Q3 2024 was $44 million (11% of sales), up from $9 million (2.4%) in Q3 2023.
Net secured leverage ratio stood at 2.8x covenant EBITDA; liquidity at $281 million.
Total debt at quarter-end was $773 million; net secured debt was $622 million.
Operating cash flow for the nine months ended September 28, 2024 was $149 million.
Outlook and guidance
2024 Adjusted EBITDA guidance remains $205–$215 million, including the Jesup fire impact.
2024 Adjusted Free Cash Flow guidance increased to $115–$125 million.
Cellulose specialties prices expected to rise low single digits in 2024 and up to 10% in 2025; volumes to increase due to competitor closure.
Paperboard and High-Yield Pulp prices expected to decline in Q4 2024, with EBITDA from these segments under pressure.
Suspension of Temiscaming HPC plant expected to improve free cash flow by $30–$35 million in 2024; one-time charges of $14 million incurred.
Latest events from Rayonier Advanced Materials
- Board refresh, CEO change, and governance reforms highlight a focus on accountability and performance.RYAM
Proxy filing20 Mar 2026 - 2026 targets positive cash flow, EBITDA growth, and new product launches amid disciplined execution.RYAM
Gabelli Funds Annual Specialty Chemicals Symposium20 Mar 2026 - 2025 results showed lower revenue and EBITDA, with 2026 targeting free cash flow recovery.RYAM
Q4 20254 Mar 2026 - Aiming to double EBITDA by 2027, leveraging price, cost, and biomaterials growth.RYAM
17th Annual Southwest IDEAS Conference3 Feb 2026 - Transformation to specialty cellulose, innovation, and sustainability drive growth and profitability.RYAM
Fireside Chat3 Feb 2026 - Shifting to specialty cellulose and biomaterials, with debt reduction and margin expansion in focus.RYAM
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Q2 net sales and earnings surged, with 2024 guidance raised and cash flow outlook improved.RYAM
Q2 20242 Feb 2026 - Shifting to specialty cellulose and biomaterials, with asset sales and debt reduction underway.RYAM
Stifel 2024 Cross Sector Insight Conference1 Feb 2026 - Focus on specialty cellulose, biomaterials, and debt reduction drives margin and cash flow growth.RYAM
Gabelli Funds' 16th Annual Specialty Chemicals Symposium26 Dec 2025